^
    Back
    Association details:
    Biomarker:ALK wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Int J Clin Oncol
    Title:

    First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

    Published date:
    08/07/2023
    Excerpt:
    Adults with stage IV/recurrent NSCLC without EGFR/ALK aberrations were randomized 1:1:1 to nivolumab plus ipilimumab...At 5-year follow-up, nivolumab plus ipilimumab continued to show long-term durable clinical benefit versus chemotherapy, regardless of tumor PD-L1 expression.
    DOI:
    https://doi.org/10.1007/s10147-023-02390-2
    Trial ID:
    CheckMate 227
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227

    Published date:
    10/12/2022
    Excerpt:
    Adults with stage IV/recurrent NSCLC without EGFR mutations or ALK alterations...were randomized....With all patients off immunotherapy treatment for ≥ 3 years, nivolumab plus ipilimumab increased 5-year survivorship versus chemotherapy, including long-term, durable clinical benefit...
    DOI:
    10.1200/JCO.22.01503
    Trial ID:
    CheckMate 227